Compare Lennar Corporation (LEN) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lennar Corporation vs TG Therapeutics Inc — how do they compare? Lennar Corporation trades at $76.69 (market cap $18.44B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Lennar Corporation is far larger — about 2.3× TG Therapeutics Inc's market cap, and Lennar Corporation pays a 2.58% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lennar Corporation for 67 Days and TG Therapeutics Inc for 16 Days on average.
| LEN | TGTX | |
|---|---|---|
Market Cap | $18.44B | $8.16B |
Volume | 6,012,214 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $133.13 | $59.06 |
52-Week Low | $74.44 | $26.94 |
Typical Hold Time | 67 Days | 16 Days |
Enterprise Value | $22.86B | $8.37B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lennar (LEN) trades at $77.6, up 1.93% on the day, but remains in a bearish technical trend with recent earnings misses and declining profitability. The stock is trading below its book value with a P/B of 0.86, indicating potential undervaluation, while Berkshire Hathaway's increasing stake to 11.2% provides notable institutional support. Revenue and net income have softened in 2025, with margins under pressure amid a challenging housing market.
The outlook is mixed: strong institutional backing and attractive valuation metrics suggest long-term opportunity, but near-term headwinds from rising mortgage rates, earnings volatility, and bearish technical signals pose risks. Analyst consensus is divided, with a $77.38 price target slightly below the current price, reflecting cautious optimism amid sector uncertainty.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% on the day, amid a bearish technical signal despite a neutral oscillator reading. The company reported strong revenue growth, with 2025 revenue at $616.29M and net income of $447.18M, though recent quarterly EPS misses and a negative net cash flow of $100.70M in 2025 highlight operational challenges. Positive news includes BRIUMVI capturing significant market share and institutional buying interest.
The outlook is mixed; robust analyst consensus (84.62% buy ratings) and a $80.50 price target suggest upside, but risks include ongoing litigation, earnings volatility, and high valuation multiples. Key catalysts are subcutaneous BRIUMVI data and potential acquisition interest, though execution risks remain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lennar Corporation
Lennar is the second-largest public homebuilder in the United States. The company's homebuilding operations target first-time, move-up, and active adult homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily construction and has invested in numerous housing-related technology startups.
Read more on LEN →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
